SCHEMBL3230248

SCHEMBL3230248

O=C1CCCN1c1cccc(NCc2ccc(Cl)cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.57
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
TSHR P16473 2/20 0.57
HPGD P15428 2/20 0.57
MAPT P10636 2/20 0.55
GAA P10253 1/20 0.54
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ALDH1A1 P00352 2/20 0.47
HTT P42858 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
PARP1 P09874 3/20 0.46
USP2 O75604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1965542 0.91 LMNA (0.49) LMNANPC1RAB9ATSHRHPGD
SCHEMBL3278560 0.89 GAA (0.57) LMNANPC1RAB9ATSHRHPGD
SCHEMBL1966538 0.81 LMNA (0.42) LMNANPC1RAB9AMAPTKMT2A
SCHEMBL1966605 0.80 PARP1 (0.49) LMNANPC1RAB9ATSHRHPGD
SCHEMBL3230238 0.79 NPC1 (0.80) LMNANPC1RAB9ATSHRHPGD
SCHEMBL6028118 0.77 ALDH1A1 (0.64) LMNANPC1RAB9ATSHRHPGD
SCHEMBL22797021 0.74 GAA (0.70) LMNANPC1RAB9ATSHRHPGD
SCHEMBL632583 0.74 GAA (0.50) LMNANPC1RAB9ATSHRHPGD
SCHEMBL8215904 0.74 FNTA (0.53) NPC1RAB9ATSHRHPGDGAA
SCHEMBL10208407 0.74 HPGD (0.54) LMNANPC1RAB9ATSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334637-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-01-04 EP claimed
US-8372840-B2 Potassium channel blockers XENTION LIMITED (GB) 2013-02-12 US claimed
US-20100087438-A1 New Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023446-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2334637-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-01-04 EP disclosed
US-8372840-B2 Potassium channel blockers XENTION LIMITED (GB) 2013-02-12 US disclosed
US-20100087438-A1 New Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023446-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087438-A1 New Potassium Channel Blockers KCNJ2, KCNB1, KCNJ11 LMNA 1376/4885NPC1 511/4885RAB9A 1126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.